Company intelligence / Profile preview

MAAB Group

Auckland or unspecified city, New Zealandmass.gov ↗

Ownership: Private
Development stage: Other

Overview

MAAB Group is an active international investment and trading company specializing in the commercialization of innovative healthcare and life science products. Their portfolio includes probiotics, alginate medical devices for reflux management, AI-driven neurology solutions, and skin allergy treatments. The company focuses on bringing novel health technologies to global markets rather than developing proprietary therapeutics through clinical trials.

Therapeutic areas: DermatologyGastroenterologyNeurology
Modalities: ProbioticsMedical device (alginate-based applications)Possibly other health-related consumer products
Industry: Therapeutic Medical Devices

Partnerships

Business deals between Western countries and China are highlighted as a core activity; specific partners not listed.

Beyond the preview

Go deeper on MAAB Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAAB Group.

Explore the full profile